

## **Technical Consultation on HIV Drug Resistance Surveillance in Latin America and the Caribbean Region**

**19-21/3/2013 - Brasilia, Brazil**

### **Purpose**

The purpose of this technical consultation is to support future implementation of harmonized and quality controlled HIVDR surveillance in the LAC region, and guide the development of a technical cooperation agenda to support HIVDR surveillance implementation.

Through plenary discussions and work groups this technical consultation will address:

- (a) priorities for HIVDR surveillance, based on use of information for public health decision-making at National Program level;
- (b) relevance and feasibility of implementation of WHO recommended HIVDR surveillance generic protocols in LAC; and
- (c) regional agenda of technical cooperation to support HIVDR surveillance in LAC.

### **Objectives**

- To review global and regional evidence of HIVDR;
- To discuss priorities for HIVDR surveillance and use of HIVDR data for decision-making from the point of view of National Programs in LAC;
- To review the WHO HIVDR surveillance strategy, and discuss the relevance and feasibility of each surveillance tool in the LAC region;
- To develop a set of recommendations for HIVDR surveillance in LAC.
- To discuss priorities and roles for a regional agenda of technical cooperation to support HIVDR surveillance in LAC.

### **Expected Outcomes**

- Consensus on priorities for HIVDR surveillance and use of HIVDR data for decision-making from the point of view of National Programs in LAC;

- Consensus on relevance and feasibility of implementation of WHO recommended HIVDR surveillance tools in LAC, and recommendations for harmonized methodologies of HIVDR surveillance in LAC.
- Consensus on priorities and roles for a technical cooperation agenda to support HIVDR surveillance in the LAC region, including the formation of a regional HIVDR working group.

### Participants (30-35)

- HIV/Aids Program Managers;
- Regional experts in HIVDR Surveillance;
- WHO HIVDR Network Laboratories;
- Partner organizations (CDC, PHAC)
- Civil society
- WHO/PAHO

**Language: English/Spanish/Portuguese (translation available)**

Day 1,		
8:00 - 8:30	Registration	
8:30 – 9:00	Welcome remarks	PAHO/WHO, Dep DST/aids/HV
9:00 – 9:15	Introduction and Objectives	PAHO
<b><u>Session 1: 9:30 – 10:30</u></b> <b>Overview of HIV Drug Resistance (HIVDR) at global and regional level.</b> Objective: review current evidence of HIVDR from global to regional perspective. Chair: Chris Archibald Rapporteur: Noreen Jack		
20 min	WHO Global HIVDR report 2012	WHO
20 min	HIVDR in Latin America and Caribbean	PAHO
20 min	Q/A – Discussion: evidence of HIVDR resistance in LAC	
10:30 – 10:50	<b>Coffee Break</b>	

## Session 2: 10:50 – 12:30

### HIV Drug Resistance Surveillance from a public health perspective in the context of Treatment 2.0.

Objective: review the WHO HIVDR Strategy and discuss its link to the Treatment 2.0 initiative at regional level. Discuss the public health purpose and use of HIVDR surveillance information for decision making (ex. ART guidelines development/update, use of genotyping, etc.).

Chair: Chris Archibald

Rapporteur: Noreen Jack

20 min	WHO HIVDR Strategy 2012 and public health actions based on HIVDR surveillance	WHO
10 min	Treatment 2.0: Regional adaptation and strategies of implementation in LAC.	PAHO
20 min	National HIVDR Strategy. Country experiences (10 minutes each): <ul style="list-style-type: none"> <li>▪ Brazil</li> <li>▪ Guyana</li> </ul>	Dirceu Greco Shanti Singh
50 min	Q/A – Discussion and Consensus building session:  Setting regional priorities for HIVDR surveillance and use of HIVDR data for decision-making from the point of view of National Programs in LAC (ex. Decision making for ART guidelines development/update, use of genotyping, etc.)	
12:30-14:00	<b>Lunch</b>	

## Session 3: 14:00 – 15:15

### Surveillance of transmitted drug resistance (TDR) in recently infected individuals

Objective: review WHO protocol for TDR surveillance in recently infected individuals and discuss its relevance and feasibility in the LAC region and adaptation at country level.

Chair: Silvia Bertagnolio

Rapporteur: Noreen Jack

15 min	Surveillance of transmitted drug resistance (TDR) in recently infected individuals	WHO
15 min	Defining recent HIV infection for TDR surveillance	CDC
20 min	Country experiences (10 minutes each): <ul style="list-style-type: none"> <li>▪ Panama</li> <li>▪ Honduras</li> </ul>	Juan Pascal Ivette Lorenzana
25 min	Q/A – Discussion: feasibility of TDR surveillance in recently infected in LAC and programmatic use of data.	
15:15 – 15:30	<b>Coffee Break</b>	

#### Session 4: 15:30 – 16:50

##### Surveillance of resistance in patients initiating HAART.

Objective: review WHO protocol for surveillance of resistance in patients initiating ART and discuss its relevance and feasibility in the LAC region and adaptation at country level.

Chair: Silvia Bertagnolio

Rapporteur: Noreen Jack

20 min	WHO protocol for surveillance of resistance in patients initiating HAART.	WHO
30 min	Country experiences (10 minutes each): <ul style="list-style-type: none"> <li>▪ Brazil</li> <li>▪ Mexico</li> <li>▪ TRT</li> </ul>	Amilcar Tanuri Santiago Àvila TRT
30 min	Q/A – Discussion: feasibility Surveillance of resistance in patients initiating HAART in LAC and programmatic use of data.	
16:50 – 17:00	Closing of first day	

#### Day 2,

8:30 – 9:00	Review of first day	Rapporteurs 1st day
-------------	---------------------	---------------------

#### Session 5: 9:00 – 10:30

##### Surveillance of acquired resistance in patients on HAART

Objective: review WHO protocol for surveillance of acquired resistance in patients on HAART and discuss its relevance and feasibility in the LAC region and adaptation at country level.

Chairs: Chunfu Yang

Rapporteur: Giovanni Ravasi

20 min	WHO cross sectional surveys for acquired resistance	WHO
20 min	Country experiences (10 minutes each): <ul style="list-style-type: none"> <li>▪ Brazil</li> <li>▪ WHO (Country simulation exercise)</li> </ul>	Marcelo Freitas Michael Jordan
50 min	Q/A – Discussion: <ul style="list-style-type: none"> <li>▪ How to measure the clinical impact of HIVDR in patients on HAART.</li> <li>▪ Feasibility of cross sectional surveys for acquired resistance in LAC and programmatic use of data.</li> </ul>	
10:30 – 10:45	<b>Coffee Break</b>	

#### Session 6: 10:45 – 12:30

##### Surveillance of initial resistance in pediatric patients <18 months of age

Objective: review WHO recommended protocol for surveillance of initial resistance in pediatric patients <18 months of age and discuss its relevance and feasibility in the LAC region and adaptation at country

level. Chairs: Chunfu Yang Rapporteur: Giovanni Ravasi		
20 min	WHO recommended protocol for surveillance of initial resistance in pediatric patients <18 months of age	WHO
20 min	Country experiences (10 minutes each): <ul style="list-style-type: none"><li>▪ Brazil</li><li>▪ Panama</li></ul>	Rodrigo Zilli Juan Pascal
50 min	Q/A – Discussion: feasibility of surveillance of initial resistance in pediatric patients <18 months of age in LAC and programmatic use of data.	
12:15 – 14:00	<b>Lunch</b>	
<b>Session 7: 14:00 – 16:45</b> <b>Work group discussion on HIVDR surveillance</b>		
14:00 – 14:30	<p>Work group formation (3 groups). Each group will discuss the relevance of WHO protocols for the LAC region, considering regional public health priorities and their feasibility in the context of concentrated epidemics. The groups should respond to the following questions:</p> <ol style="list-style-type: none"><li>1. Which HIVDR surveillance protocols should be prioritized, based on identified public health priorities at National Program level and feasibility in the LAC region?</li><li>2. Which are the most relevant challenges for the implementation of harmonized and quality controlled HIVDR surveillance in the region?</li><li>3. Which are the most relevant challenges for the programmatic use of HIVDR surveillance data to support decision making at National Program level ?</li><li>4. Recommendations from the group about technical cooperation needs to support harmonized and quality controlled HIVDR surveillance in the region.</li></ol>	
14:30 - 16:45	Group work	
16:45 – 17:00	Closing of second day	
<b>Day 3,</b>		
8:30 – 9:00	Review of second day	Rapporteurs 2nd day
<b>Session 8: 9:00 – 10:30</b> <b>Consensus building session on prioritization of HIVDR surveillance protocols in the LAC region.</b> Objective: building consensus on recommendations for HIVDR surveillance based on identified public health priorities, challenges for implementation of harmonized protocols with quality control and use of data for public health actions in LAC Chairs: Paul Sandstrom		

Rapporteurs: Michael Jordan, Pamela Bermudez		
9:00 – 09:45	Presentation of groups (15 min presentation for each group)	
09:45 – 10:30	Consensus building session on prioritization of HIVDR surveillance protocols in the LAC region.	
10:30 – 10:45	<b>Coffee Break</b>	
<b>Session 9: 10:45 – 12:15</b> <b>Perspectives of technical cooperation to support HIVDR surveillance in the LAC region</b> Objective: Discuss priorities and roles for a technical cooperation agenda to support HIVDR surveillance in the region. Chairs: Paul Sandstrom Rapporteurs: Michael Jordan, Pamela Bermudez		
10:45 – 11:00	<ul style="list-style-type: none"><li>▪ WHO HIVDR Lab Network Update</li></ul>	WHO
11:00 – 11:45	Plenary session to discuss areas of technical cooperation to support HIVDR surveillance in LAC: <ul style="list-style-type: none"><li>▪ Technical cooperation for lab capacity building for genotyping, including quality assurance;</li><li>▪ Technical support to implement HIVDR surveillance in LAC;</li><li>▪ Development of a regional HIVDR working group.</li></ul>	
11:45-12:15	Consensus building session on priorities and roles for a technical cooperation agenda to support HIVDR surveillance in the region.	
12:15 – 12:30	Closing remarks	
12:30 – 14:00	<b>Lunch</b>	